Podcast
FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC
Author(s):
In Partnership With:
Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Melissa L. Johnson, MD, the director for lung cancer research at Sarah Cannon Research Institute at Tennessee Oncology and chair of the Cancer Committee at TriStar Centennial Medical Center in Nashville, Tennessee. Dr Johnson joined us to talk about the FDA approval of tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and chemotherapy in non–small cell lung cancer (NSCLC).
On November 10, 2022, the FDA granted approval to the combination of tremelimumab, durvalumab, and platinum-based chemotherapy in adults with metastatic NSCLC without sensitizing EGFR mutations or ALK aberrations. This approval was supported by findings from the phase 3 POSEIDON trial (NCT03164616), in which the combination resulted in a 23% reduction in the risk of death over chemotherapy alone.
In our exclusive interview, Dr Johnson discussed the significance of this approval, shared key data from POSEIDON, and noted the combination’s efficacy and tolerability in various patient populations.
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
